A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor

Journal of Lipid Research

Volumn 39, Issue 1, 1998, Pages 17-30

  Bisgaier, Charles L ^a   Essenburg, Arnold D ^a   Barnett, Blake C ^a   Auerbach, Bruce J ^a   Haubenwallner, Sabine ^a   Leff, Todd ^a   White, Andrew D ^a   Creger, Paul ^a   Pape, Michael E ^b   Rea, Thomas J ^b   Newton, Roger S ^a  

^a Dept of Vasc and Cardiac Diseases ^*  (United States)

^b PFIZER INC   (United States)

Author keywords

apoG III; Fibrates; Gemfibrozil; HepG2 cells; Lipoproteins; PD72953; Triglyceride

Indexed keywords

2,2,12,12 TETRAMETHYLTRIDECANOIC ACID; 6,6' OXYBIS(2,2 DIMETHYLHEXANOIC ACID); ANTILIPEMIC AGENT; CARNITINE ACETYLTRANSFERASE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PD 69405; PD 72953; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL METABOLISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIPID LIVER LEVEL; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; APOLIPOPROTEINS E; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; GEMFIBROZIL; HEXANOIC ACIDS; HUMANS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 15444357807     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. LaRosa, J. C. 1990. At what levels of total low-or high-density lipoprotein cholesterol should diet/drug therapy be initiated? United States Guidelines. Am. J. Cardiol. 65: 7F-10F.
2. Gaw, A., and J. Shepherd. 1991. Fibric acid derivatives. Curr. Opin. Lipidol. 2: 39-42.
3. Larsen, M. L., and D. R. Illingworth. 1993. Triglyceride-lowering agents: fibrates and nicotinic acid. Curr. Opin. Lipidol. 4: 34-40.
4. Staels, B., N. Vu-Dac, V. A. Kosykh, R. Saladin, J-C. Fruchart, J. Dallongeville, and J. Auwerx. 1995. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 95: 705-712.
5. Haubenwallner, S., A. D. Essenburg, B. C. Barnett, M. E. Pape, R. B. DeMattos, B. R. Krause, L. L. Minton, B. J. Auerbach, R. S. Newton, T. Leff, and C. L. Bisgaier. 1995. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J. Lipid Res. 36: 2541-2551.
6. Schoonjans, K., B. Staels, and J. Auwerx. 1996. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37: 907-925.
7. Hertz, R., J. Bishara-Shieban, and J. Bar-Tana. 1995. Mode of action of peroxisome proliferators as hypolipidemic drugs. Supression of apolipoprotein C-III. J. Biol. Chem. 270: 13470-13475.
8. Krause, B. R., B. C. Barnett, A. D. Essenburg, K. A. Kieft, B. J. Auerbach, R. Bousley, R. Stanfield, R. S. Newton, and C. L. Bisgaier. 1996. Opposite effects of bezafibrate and gembifrozil in both normal and hypertriglyceridemic rats. Atherosclerosis. 127: 91-101.
9. Krause, B. R., and R. S. Newton. 1985. Apolipoprotein changes assiciated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats. J. Lipid Res. 26: 940-949.
10. Staels, B., A. van Tol, T. Andreu, and J. Auwerx. 1992. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler. Thromb. 12: 286-294.
11. Eisenberg, S., and D. Rachmilewitz. 1975. Interaction of rat plasma very low density lipoprotein with lipoprotein lipase-rich (postheparin) plasma. J. Lipid Res. 16: 341-351.
12. Blanchette-Mackie, E. J., and R. O. Scow. 1976. Retention of lipolytic products in chylomicrons incubated with lipoprotein lipase: electron microscope study. J. Lipid Res. 17: 57-67.
13. Tall, A. R., and D. M. Small. 1980. Body cholesterol removal: role of plasma high-density lipoproteins. Adv. Lipid Res. 17: 1-51.
14. Tall, A. R., and P. H. R. Green. 1981. Incorportation of phosphatidylcholine into spherical and discoidal lipoproteins during incubation of egg phosphatidylcholine vesicles with isolated high density lipoproteins or with plasma. J. Biol. Chem. 256: 2035-2044.
15. Tall, A. R., P. H. R. Green, R. M. Glickman, and J. W. Riley. 1979. Metabolic fate of chylomicron phospholipids and apolipoproteins in the rat. J. Clin. Invest. 64: 977-989.
16. Hamilton, R. L., M. C. Williams, C. J. Fielding, and R. J. Havel. 1976. Discoidal bilayer structure of nascent high density lipoproteins from perfused rat liver. J. Clin. Invest. 58: 667-680.
17. Johnson, G. L., L. L. Swift, and L. L. Rudel. 1987. Nascent lipoproteins from recirculating and nonrecirculating liver perfusions and from the hepatic Golgi apparatus of African green monkeys. J. Lipid Res. 28: 549-564.
18. Bearnot, H. R., R. M. Glickman, L. Weinberg, P. H. R. Green, and A. R. Tall. 1982. Effect of a biliary diversion on mesenteric lymph apolipoprotein A-I and high density lipoproteins. J. Clin. Invest. 69: 210-217.
19. Forester, G. P., A. R. Tall, G. L. Bisgaier, and R. M. Glickman. 1983. Rat intestine secretes spherical high density lipoproteins. J. Biol. Chem. 258: 5938-5943.
20. Bisgaier, C. L., and R. M. Glickman. 1983. Intestinal synthesis, secretion, and transport of lipoproteins. Annu. Rev. Physiol. 45: 625-636.
21. Holt, P. R., and A. A. Dominguez. 1980. Triton-induced hyperlipidemia: a model for studies of intestinal lipoprotein production. Am. J. Physiol. 238:G453-G457.
22. Kuusi, T., E. A. Nikkila, M-R. Taskinen, P. Somerharju, and C. Ehnholm. 1982. Human postheparin plasma hepatic lipase activity against triavylglycerol and phospholipid substrates. Clin. Chim. Acta. 122: 39-45.
23. Bilheimer, D. W., S. Eisenberg, and R. I. Levy. 1972. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim. Biophys. Acta. 260: 212-221.
24. McFarlane, A. S. 1958. Efficient trace-labelling of proteins with iodine. Nature. 182: 53-57.
25. Egusa, G., D. W. Brady, S. M. Grundy, and B. V. Howard. 1983. Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein apolipoprotein B. J. Lipid Res. 24: 1261-1267.
26. Kieft, K. A., T. M. A. Bocan, and B. R. Krause. 1991. Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel-filtration chromatography. J. Lipid Res. 32: 859-866.
27. Krause, B. R., R. Bousley, K. Kieft, D. Robertson, R. Stanfield, E. Urda, and R. S. Newton. 1994. Comparison of lifibrol to other lipid regulating agents in experimental animals. Pharmacol. Res. 29: 345-357.
28. Pape, M. E., G. W. Melchior, and K. R. Marotti. 1991. mRNA quantitation by a simple and sensitive RNAse protection assay. Genet. Anal. 8: 206-213.
29. Rea, T. J., R. B. Demattos, and M. E. Pape. 1993. Hepatic expression of genes regulating lipid metabolism in rabbits. J. Lipid Res. 34: 1901-1910.
30. Marrino, P., D. Gavish, E. Shafrir, and S. Eisenberg. 1987. Diurnal variations of plasma lipids, tissue and plasma lipoprotein lipase, and VLDL secretion rates in the rat. A model for studies of VLDL metabolism. Biochim. Biophys. Acta. 920: 277-284.
31. Auwerx, J. 1993. Regulation of gene expression by fatty acids and fibric acid derivatives: an integrative role for peroxisome proliferator activated receptors. Horm. Res. 38: 269-277.
32. Schoonjans, K., J. Peinado-Onsurbe, A.-M. Lefebvre, R. A. Heyman, M. Briggs, S. Deeb, B. Staels, and J. Auwerx. 1996. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15: 5336-5348.
33. Kliewer, S. A., J. M. Lenhard, T. M. Wilson, I. Patel, D. C. Morris, and J. Lehmann. 1995. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83: 813-819.
34. Havel, R. 1994. McCollum Award Lecture, 1993: Triglyceride-rich lipoproteins and atherosclerosis - new perspectives. Am. J. Clin. Nutr. 59: 795-799.
35. Lindenstrøm, E., G. Boysen, and J. Nyboe. 1994. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. Br. Med. J. 309: 11-15.
36. Zilversmit, D. B. 1995. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin. Chem. 41: 153-158.
37. Consensus Development Panel. 1992. Triglyceride, high density lipoprotein, and coronary heart disease. NIH Consensus Statement. 10: 1-28.
38. Frick, M. H., O. Elo, K. Haapa, O. P. Heinonen, P. Heinsalmi, P. Helo, J. K. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, H. Mäenpää, M. Mälkönen, M. Mänttäri, S. Norola, A. Pasternack, J. Pikkarainen, M. Romo, T. Sjöblom, and E. A. Nikkilä. 1987. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317: 1237-1245.
39. Windler, E., Y-S. Chao, and R. J. Havel. 1980. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins. J. Biol. Chem. 255: 8303-8307.
40. Berthou, L., N. Duverger, F. Emmanuel, S. Langouët, J. Auwerx, A. Guillouzo, J-C. Fruchart, E. Rubin, P. Denèfle, B. Staels, and D. Branellec. 1996, Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J. Clin. Invest. 97: 2408-2416.
41. Vu-Dac, N., K. Schoonjans, B. Laine, J-C. Fruchart, J. Aureux, and B. Staels. 1994. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J. Biol. Chem. 269: 31012-31018.
42. Ockner, R. K., R. M. Kaikaus, and N. M. Bass. 1993. Fatty-acid metabolism and the pathogenesis of hepatocellular carcinoma: review and hypothesis. Hepatology. 18: 669-676.
43. Yu, K., W. Bayona, C. B. Kallen, H. P. Harding, C. P. Ravera, G. McMahon, M. Brown, and M. A. Lazar. 1995. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270: 23975-23938.
44. Tontonoz, P., E. Hu, and B. M. Spiegelman. 1994. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell. 79: 1147-1156.
45. 2 is a ligand for the adipocyte determination factor PPAγ Cell. 83: 803-812.
46. 4 pathway to inflammation control. Nature. 384: 39-43.
47. Cohen, A. J., and P. Grasso. 1981. Review of the hepatic response to hypolipidaemic drugs in rodents and assessment of its toxicological significance to man. Food Cosmet. Toxicol. 19: 585-605.
48. De La Iglesia, F. A., J. E. Lewis, R. A. Buchanan, E. L. Marcus, and G. McMahon. 1982. Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis. 43: 19-37.
49. Hanefeld, M., C. Kemmer, and E. Kadner. 1983. Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis. 46: 239-246.
50. Gariot, P., E. Barrat, L. Mejean, J. P. Pointel, P. Drouin, and G. Debry. 1983. Fenofibrate and human liver. Lack of proliferation of peroxisomes. Arch. Toxicol. 53: 151-163.
51. Blümcke, S., W. Schwartzkopff, H. Lobeck, N. A. Edmondson, D. E. Prentice, and G. F. Blane. 1983. Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis. 46: 105-116.
52. Reddy, J., R. L. Jirtle, T. K. Watanabe, N. K. Reddy, G. Michalopoulos, and S. A. Qureshi. 1984. Response of hepatocytes transplanted into syngeneic hosts and heterotransplanted into athymic nude mice to peroxisome proliferators. Cancer Res. 44: 2582-2589.
53. Hertz, R., J. Arnon, A. Hoter, D. Shouval, and J. Bat-Tana. 1987. Clofibrate does not induce peroxisomal proliferation in human hepatoma cell lines PLC/PRF/5 and SK-HEP-1. Cancer Lett. 34: 263-272.
54. Reddy, J. K., N. D. Lalwani, S. A. Qureshi, M. K. Reddy, and C. M. Moehle. 1984. Induction of hepatic peroxisomal proliferation in nonrodent species, including primates. Am. J. Pathol. 114: 171-183.
55. Lee, S. S.-T., T. Pineau, J. Drago, E. J. Lee, J. W. Owens, D. L. Kroetz, P. M. Fernandez-Salguero, H. Westphal, and F. Gonzalez. 1995. Targeted disruption of the a isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15: 3012-3022.
56. Fan, J., J. Wang, A. Bensadoun, S. J. Lauer, Q. Dang, R. W. Mahley, and J. M. Taylor. 1994. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc. Natl. Acad. Sci. USA. 91: 8724-8728.
57. Busch, S. J., R. L. Barnhart, G. A. Martin, M. C. Fitzgerald, M. T. Yates, S. J. T. Mao, C. E. Thomas, and R. L. Jackson. 1994. Human hepatic triglyceride Iipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J. Biol. Chem. 269: 16376-16382.
58. Wang, C-S., W. J. McConathy, H. U. Kloer, and P. Alaupovic. 1985. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J. Clin. Invest. 75: 384-390.